NANOPARTICLE-BASED DOXORUBICIN DELIVERY SYSTEMS FOR IMPROVED CANCER TREATMENT

Chemotherapy, especially doxorubicin, is a key component of treatment for cancer, which continues to be a major cause of morbidity and death globally. Dose-dependent toxicities, including as cardiotoxicity, myelosuppression, and the emergence of drug resistance, restrict the therapeutic usage of doxorubicin despite its strong anticancer efficacy. By improving solubility, stability, and bioavailability while permitting targeted administration to tumor regions, nanoparticle-based delivery systems have emerged as a viable approach to get around these restrictions. When compared to free doxorubicin, a number of platforms, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, micelles, and dendrimers, have shown better pharmacokinetics, greater tumor accumulation, and decreased systemic toxicity. To guarantee the best possible therapeutic results, these nanoparticles must be thoroughly characterized in terms of their size, shape, surface charge, drug loading, and release kinetics. Preclinical research has demonstrated that doxorubicin encapsulated in nanoparticles increases cytotoxicity against cancer cells, more successfully slows tumor development, and reduces off-target effects. To achieve synergistic anticancer effects, these systems can also be combined with combination therapies like radiation or immunotherapy. Despite their potential, there are still issues with large-scale production, safety assessment, regulatory approval, and customized application, which emphasizes the necessity of ongoing research and development. All things considered, doxorubicin delivery systems based on nanoparticles present a potent strategy to enhance the safety and effectiveness of chemotherapy, opening the door to more accurate, efficient, and patient-friendly cancer treatments.